Cyclohexanecarboxylic acid, 4-(4-chloro-6-methyl-2-pyrimidinyl)-1-methoxy-, methyl ester

Its uses include helping to construct the central cyclohexyl-pyrimidinyl core of the molecule, which is subsequently converted into the final active pharmaceutical ingredient (API) by introducing the 5-methyl-1H-pyrazol-3-yl amino group. Cyclohexanecarboxylic acid, 4-(4-chloro-6-methyl-2-pyrimidinyl)-1-methoxy-, methyl ester (CAS 2778223-48-4) is a key intermediate in the synthesis of Pralsetinib, a targeted cancer therapy.